CA1064396A
(en)
|
1975-02-18 |
1979-10-16 |
Myer L. Coval |
Fractional precipitation of gamma globulin with polyethylene glycol
|
US4075193A
(en)
|
1976-11-26 |
1978-02-21 |
Parke, Davis & Company |
Process for producing intravenous immune globulin
|
US4374763A
(en)
|
1979-09-17 |
1983-02-22 |
Morishita Pharmaceutical Co., Ltd. |
Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4499073A
(en)
|
1981-08-24 |
1985-02-12 |
Cutter Laboratories, Inc. |
Intravenously injectable immune serum globulin
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4597966A
(en)
|
1985-01-09 |
1986-07-01 |
Ortho Diagnostic Systems, Inc. |
Histidine stabilized immunoglobulin and method of preparation
|
US4966852A
(en)
|
1987-07-23 |
1990-10-30 |
Monsanto Company |
DNA clone of human tissue factor inhibitor
|
EP0303746B2
(en)
|
1987-08-21 |
1998-12-02 |
Mallinckrodt Group Inc. |
Stabilization of growth promoting hormones
|
US4877608A
(en)
|
1987-11-09 |
1989-10-31 |
Rorer Pharmaceutical Corporation |
Pharmaceutical plasma protein formulations in low ionic strength media
|
US5096885A
(en)
|
1988-04-15 |
1992-03-17 |
Genentech, Inc. |
Human growth hormone formulation
|
EP0417193B1
(en)
|
1988-05-27 |
1993-08-04 |
Centocor, Inc. |
Freeze-dried formulation for antibody products
|
CA2049342A1
(en)
|
1989-03-27 |
1990-09-28 |
Sally Bolmer |
Formulations for stabilizing of igm antibodies
|
US6969586B1
(en)
|
1989-05-16 |
2005-11-29 |
Scripps Research Institute |
Method for tapping the immunological repertoire
|
US5217954A
(en)
|
1990-04-04 |
1993-06-08 |
Scios Nova Inc. |
Formulations for stabilizing fibroblast growth factor
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
DK261490D0
(da)
|
1990-10-31 |
1990-10-31 |
Novo Nordisk As |
New pharmaceutical compound
|
JPH0565233A
(ja)
|
1991-03-08 |
1993-03-19 |
Mitsui Toatsu Chem Inc |
モノクローナル抗体含有凍結乾燥製剤
|
US6165467A
(en)
|
1991-07-20 |
2000-12-26 |
Yoshihide Hagiwara |
Stabilized human monoclonal antibody preparation
|
GB9122820D0
(en)
|
1991-10-28 |
1991-12-11 |
Wellcome Found |
Stabilised antibodies
|
EP0539975A1
(en)
|
1991-10-31 |
1993-05-05 |
Teijin Limited |
Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
|
US5849700A
(en)
|
1991-12-20 |
1998-12-15 |
Novo Nordisk A/S |
Pharmaceutical formulation
|
DE4223132A1
(de)
|
1992-07-14 |
1994-01-20 |
Deutsche Aerospace |
Verfahren zur Schrittakt-Regeneration bei der Demodulation von digital modulierten Signalen und Anordnung zum Ausführen des Verfahrens
|
JPH06153985A
(ja)
|
1992-11-16 |
1994-06-03 |
Teijin Ltd |
モノクローナル抗体
|
ATE197550T1
(de)
|
1993-02-23 |
2000-12-15 |
Genentech Inc |
Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff
|
US5455338A
(en)
|
1993-11-05 |
1995-10-03 |
Zymogenetics, Inc. |
DNA encoding novel human kunitz-type inhibitors and methods relating thereto
|
DE4344824C1
(de)
|
1993-12-28 |
1995-08-31 |
Immuno Ag |
Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung
|
US5580856A
(en)
|
1994-07-15 |
1996-12-03 |
Prestrelski; Steven J. |
Formulation of a reconstituted protein, and method and kit for the production thereof
|
JPH0875736A
(ja)
|
1994-09-06 |
1996-03-22 |
Chemo Sero Therapeut Res Inst |
ヒト組織因子凝固系インヒビターの定量法
|
GB9418092D0
(en)
|
1994-09-08 |
1994-10-26 |
Red Cross Found Cent Lab Blood |
Organic compounds
|
US6111079A
(en)
|
1995-06-05 |
2000-08-29 |
Bionebraska, Inc. |
Lead binding polypeptides and nucleotides coding therefore
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
CN102416176A
(zh)
|
1995-07-27 |
2012-04-18 |
基因技术股份有限公司 |
稳定等渗的冻干蛋白质制剂
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US5902582A
(en)
|
1995-09-05 |
1999-05-11 |
Chiron Corporation |
Use of TFPI inhibitor for treatment of cancer
|
US6686191B1
(en)
|
1995-09-22 |
2004-02-03 |
Bayer Healthcare Llc |
Preparation of virally inactivated intravenously injectable immune serum globulin
|
US7368111B2
(en)
*
|
1995-10-06 |
2008-05-06 |
Cambridge Antibody Technology Limited |
Human antibodies specific for TGFβ2
|
JP3681206B2
(ja)
*
|
1995-12-26 |
2005-08-10 |
株式会社三菱化学ヤトロン |
抗ファクターXa・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
|
CZ234898A3
(cs)
|
1996-01-25 |
1998-11-11 |
Schering Aktiengesellschaft |
Zdokonalené koncentrované injekční a infusní roztoky pro intravazální použití
|
US5770700A
(en)
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
KR100236393B1
(ko)
|
1996-02-02 |
1999-12-15 |
나까니시 히로유끼 |
사람성장호르몬을 함유하는 의약제제
|
TWI240627B
(en)
|
1996-04-26 |
2005-10-01 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
US20040052799A1
(en)
|
1996-11-15 |
2004-03-18 |
Astra Aktiebolag |
Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
US6593291B1
(en)
|
1997-02-06 |
2003-07-15 |
Entremed, Inc. |
Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
|
WO1998042850A1
(en)
|
1997-03-26 |
1998-10-01 |
Rpms Technology Limited |
Anticoagulant fusion protein anchored to cell membrane
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6531298B2
(en)
|
1997-07-21 |
2003-03-11 |
The University Of North Carolina At Chapel Hill |
Factor IX antihemophilic factor with increased clotting activity
|
US6617156B1
(en)
|
1997-08-15 |
2003-09-09 |
Lynn A. Doucette-Stamm |
Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
|
CA2302708A1
(en)
|
1997-08-21 |
1999-03-04 |
Siemens Aktiengesellschaft |
Method for transmitting user data that can be allocated to different applications
|
US6551795B1
(en)
|
1998-02-18 |
2003-04-22 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
|
AU3006799A
(en)
|
1998-03-12 |
1999-09-27 |
Human Genome Sciences, Inc. |
31 human secreted proteins
|
GB9820525D0
(en)
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
US20040031072A1
(en)
|
1999-05-06 |
2004-02-12 |
La Rosa Thomas J. |
Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
|
US20100293669A2
(en)
|
1999-05-06 |
2010-11-18 |
Jingdong Liu |
Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
|
US20090087878A9
(en)
|
1999-05-06 |
2009-04-02 |
La Rosa Thomas J |
Nucleic acid molecules associated with plants
|
WO2001024814A1
(en)
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
US20050208558A1
(en)
|
1999-10-19 |
2005-09-22 |
Applera Corporation |
Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
|
JP4623825B2
(ja)
|
1999-12-16 |
2011-02-02 |
協和発酵バイオ株式会社 |
新規ポリヌクレオチド
|
US20020160934A1
(en)
|
2000-01-14 |
2002-10-31 |
Julie Broadus |
Nucleic acid sequences from Drosophila melanogaster that encode proteins essential for larval viability and uses thereof
|
US20030232054A1
(en)
|
2000-01-25 |
2003-12-18 |
Tang Y. Tom |
Novel nucleic acids and polypeptides
|
EP1260230A4
(en)
|
2000-02-29 |
2008-08-06 |
Chugai Pharmaceutical Co Ltd |
LONG-TERM STABILIZED PREPARATIONS
|
AU5133601A
(en)
|
2000-04-07 |
2001-10-23 |
Ellis L Kline |
Methods and compositions for treating neoplasms
|
US20110131679A2
(en)
|
2000-04-19 |
2011-06-02 |
Thomas La Rosa |
Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
|
US7834146B2
(en)
|
2000-05-08 |
2010-11-16 |
Monsanto Technology Llc |
Recombinant polypeptides associated with plants
|
US20040181830A1
(en)
|
2001-05-07 |
2004-09-16 |
Kovalic David K. |
Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
|
US7015194B2
(en)
|
2000-05-10 |
2006-03-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising factor VIIa and anti-TFPI
|
US20020082206A1
(en)
|
2000-05-30 |
2002-06-27 |
Leach Martin D. |
Novel polynucleotides from atherogenic cells and polypeptides encoded thereby
|
PT2281843T
(pt)
|
2000-06-16 |
2017-01-02 |
Human Genome Sciences Inc |
Anticorpos que se ligam imunoespecificamente a blys
|
EP1336410A4
(en)
|
2000-08-04 |
2005-10-12 |
Chugai Pharmaceutical Co Ltd |
PROTEIN INJECTION PREPARATIONS
|
AU2001277781A1
(en)
|
2000-08-11 |
2002-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing preparations
|
AU2001282607B2
(en)
|
2000-09-01 |
2006-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Solution preparations stabilized over long time
|
ES2332402T5
(es)
|
2000-10-12 |
2018-05-14 |
Genentech, Inc. |
Formulaciones de proteína concentradas de viscosidad reducida
|
US7214786B2
(en)
|
2000-12-14 |
2007-05-08 |
Kovalic David K |
Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
|
GB0101879D0
(en)
|
2001-01-24 |
2001-03-07 |
Enzyme Res Lab Ltd |
Anticoagulants and their uses
|
WO2002094867A2
(fr)
|
2001-02-07 |
2002-11-28 |
Institut Pasteur |
Sequence du genome de photorhabdus luminescens souche tto1 et utilisations
|
GB0103424D0
(en)
|
2001-02-12 |
2001-03-28 |
Chiron Spa |
Gonococcus proteins
|
US7667004B2
(en)
*
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
US6891085B2
(en)
|
2001-04-20 |
2005-05-10 |
Pioneer Hi-Bred International, Inc. |
Nucleic acid encoding the FUS6 antimicrobial polypeptide of Agrotis ipsilon and its use to enhance disease resistance in a plant
|
EP1390507A2
(en)
|
2001-05-21 |
2004-02-25 |
Ecopia Biosciences Inc. |
Genes and proteins involved in the biosynthesis of enediyne ring structures
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
CA2454587C
(en)
|
2001-07-25 |
2012-11-13 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
US20040142325A1
(en)
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
EP1369431A4
(en)
*
|
2001-10-15 |
2005-01-12 |
Kirin Brewery |
ANTI-HLA-DR ANTIBODIES
|
CN1604788B
(zh)
|
2001-10-16 |
2013-04-17 |
里克斯金蒂克斯公司 |
高浓度蛋白制剂及其制备方法
|
US20040029129A1
(en)
|
2001-10-25 |
2004-02-12 |
Liangsu Wang |
Identification of essential genes in microorganisms
|
AU2002363253A1
(en)
|
2001-11-01 |
2003-05-12 |
Gpc Biotech Inc. |
Endothelial-cell binding peptides for diagnosis and therapy
|
JP5290489B2
(ja)
|
2001-11-08 |
2013-09-18 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Igg抗体の安定な液体医薬製剤
|
US20050203280A1
(en)
|
2001-11-29 |
2005-09-15 |
Mcmichael John C. |
Alloiococcus otitidis open reading frames (orfs) encoding polypeptide antigens, immunogenic compositions and uses thereof
|
US20030138416A1
(en)
|
2001-12-03 |
2003-07-24 |
Jesper Lau |
Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
|
US20050108791A1
(en)
|
2001-12-04 |
2005-05-19 |
Edgerton Michael D. |
Transgenic plants with improved phenotypes
|
US7452539B2
(en)
|
2001-12-19 |
2008-11-18 |
Genentech, Inc. |
Stabilizing polypeptides which have been exposed to urea
|
EP1468118A4
(en)
|
2002-01-31 |
2006-08-02 |
Millennium Pharm Inc |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
|
EP2311489A3
(en)
|
2002-02-14 |
2013-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Formulation of antibody-containing solutions comprising a sugar as a stabilizer
|
US7314974B2
(en)
|
2002-02-21 |
2008-01-01 |
Monsanto Technology, Llc |
Expression of microbial proteins in plants for production of plants with improved properties
|
MXPA04008215A
(es)
|
2002-02-27 |
2004-11-26 |
Immunex Corp |
Formulacion polipeptidica.
|
US20060068386A1
(en)
|
2002-03-04 |
2006-03-30 |
Alexei Slesarev |
Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof
|
US7074559B2
(en)
|
2002-03-06 |
2006-07-11 |
Refents of the University of Minnesota |
Mycobacterial diagnostics
|
AU2005254062B2
(en)
|
2002-04-11 |
2011-02-17 |
Medimmune, Llc |
High pressure spray-dry of bioactive materials
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
EP1551875A4
(en)
|
2002-06-21 |
2006-06-28 |
Biogen Idec Inc |
TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
|
WO2004003144A2
(en)
|
2002-07-01 |
2004-01-08 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
EP1539212A4
(en)
|
2002-07-12 |
2007-05-02 |
Medarex Inc |
METHOD AND COMPOSITIONS FOR PREVENTING OXIDATIVE DEGRADATION OF PROTEINS
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
DE10239073A1
(de)
|
2002-08-26 |
2004-03-11 |
Basf Ag |
Verfahren zur fermentativen Herstellung schwefelhaltiger Feinchemikalien
|
CA2501626A1
(en)
|
2002-10-08 |
2004-04-22 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
|
KR100542401B1
(ko)
|
2002-10-23 |
2006-01-11 |
한국전자통신연구원 |
인터넷 차별 서비스 망에서의 연결 수락 제어방법
|
CN1878795A
(zh)
|
2002-12-02 |
2006-12-13 |
阿布格尼克斯公司 |
针对磷脂酶a2的抗体及其应用
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
CN102746399B
(zh)
|
2002-12-24 |
2016-03-02 |
里纳特神经***学公司 |
抗ngf抗体及其使用方法
|
CA2515583C
(en)
|
2003-03-07 |
2015-07-14 |
Diversa Corporation |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
CN1798575A
(zh)
|
2003-04-04 |
2006-07-05 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
CN1816351A
(zh)
*
|
2003-06-27 |
2006-08-09 |
艾伯吉尼斯公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
WO2005019266A2
(en)
|
2003-07-15 |
2005-03-03 |
Amgen Inc. |
Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
|
RS53476B
(sr)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Sredstva za specifično vezivanje faktora rasta hepatocita
|
US7871610B2
(en)
|
2003-08-12 |
2011-01-18 |
Dyax Corp. |
Antibodies to Tie1 ectodomain
|
US20060107345A1
(en)
|
2003-09-30 |
2006-05-18 |
Nickolai Alexandrov |
Sequence-determined DNA fragments and corresponding polypeptides encoded thereby
|
EP3006463A1
(en)
|
2003-10-01 |
2016-04-13 |
Kyowa Hakko Kirin Co., Ltd. |
Method for stabilizing antibody and stabilized solution-type antibody preparation
|
CA2445743A1
(en)
|
2003-10-08 |
2005-04-08 |
The University Of British Columbia |
Methods for modulating neuronal responses
|
EP1532983A1
(en)
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
CA2547569C
(en)
|
2003-12-03 |
2013-04-16 |
University Of Rochester |
Recombinant factor viii having increased specific activity
|
EP1712240B1
(en)
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stable water-based medicinal preparation containing antibody
|
EP2284184A3
(en)
|
2004-01-09 |
2011-05-18 |
Novozymes, Inc. |
Bacillus YvmA inactivation
|
US20060041961A1
(en)
|
2004-03-25 |
2006-02-23 |
Abad Mark S |
Genes and uses for pant improvement
|
NZ550366A
(en)
|
2004-05-27 |
2009-11-27 |
Crucell Holland Bv |
Binding molecules capable of neutralizing rabies virus and uses thereof
|
AU2005271892A1
(en)
|
2004-07-10 |
2006-02-16 |
Alexion Pharmaceuticals, Inc. |
Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
|
US20080008719A1
(en)
|
2004-07-10 |
2008-01-10 |
Bowdish Katherine S |
Methods and compositions for the treatment of prostate cancer
|
US20060075522A1
(en)
|
2004-07-31 |
2006-04-06 |
Jaclyn Cleveland |
Genes and uses for plant improvement
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20080148432A1
(en)
|
2005-12-21 |
2008-06-19 |
Mark Scott Abad |
Transgenic plants with enhanced agronomic traits
|
US7973140B2
(en)
|
2004-12-21 |
2011-07-05 |
Medimmune Limited |
Antibodies directed to angiopoietin-2 and uses thereof
|
AU2006208286A1
(en)
|
2005-01-26 |
2006-08-03 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
ES2381203T3
(es)
|
2005-01-27 |
2012-05-24 |
Novimmune Sa |
Anticuerpos anti-interferón gamma humanos y métodos de uso de los mismos
|
TW200638943A
(en)
|
2005-01-28 |
2006-11-16 |
Wyeth Corp |
Stabilized liquid polypeptide formulations
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
ES2905923T3
(es)
|
2005-02-08 |
2022-04-12 |
Genzyme Corp |
Anticuerpos de TGFbeta
|
US8088976B2
(en)
|
2005-02-24 |
2012-01-03 |
Monsanto Technology Llc |
Methods for genetic control of plant pest infestation and compositions thereof
|
CA2598792A1
(en)
|
2005-03-02 |
2006-09-08 |
Metanomics Gmbh |
Process for the production of fine chemicals
|
CN101184775A
(zh)
|
2005-03-04 |
2008-05-21 |
伊利诺斯大学理事会 |
凝血及纤溶级联***的调控剂
|
EP1871806A2
(en)
|
2005-03-08 |
2008-01-02 |
Pharmacia & Upjohn Company LLC |
ANTI-MAdCAM ANTIBODY COMPOSITIONS
|
WO2006096489A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Anti-m-csf antibody compositions having reduced levels of endotoxin
|
US7785595B2
(en)
|
2005-04-18 |
2010-08-31 |
Yeda Research And Development Company Limited |
Stabilized anti-hepatitis B (HBV) antibody formulations
|
US7889636B2
(en)
|
2005-05-24 |
2011-02-15 |
Cisco Technology, Inc. |
System and method for implementing a mid-call policy in a RSVP environment
|
GB2426887B
(en)
|
2005-06-04 |
2009-01-07 |
Ibm |
Client responsibilities in messaging systems
|
EP2264162A1
(en)
|
2005-07-02 |
2010-12-22 |
Arecor Limited |
Stable aqueous systems comprising proteins
|
CA2615122A1
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
US7790679B2
(en)
|
2005-08-05 |
2010-09-07 |
Amgen Inc. |
Pharmaceutical formulations
|
US20070086433A1
(en)
|
2005-10-19 |
2007-04-19 |
Cunetto Philip C |
Methods and apparatus for allocating shared communication resources to outdial communication services
|
AU2006315026B2
(en)
|
2005-11-21 |
2012-11-22 |
Sanofi Pasteur Limited |
Stabilizing formulations for recombinant viruses
|
EP1957540B1
(en)
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
US7669228B2
(en)
|
2005-12-27 |
2010-02-23 |
Cisco Technology, Inc. |
System and method for changing network behavior based on presence information
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
STABILIZER PREPARATION CONTAINING ANTIBODIES
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
DE102006005094A1
(de)
|
2006-02-04 |
2007-08-09 |
Degussa Gmbh |
Titandioxid und Polycarboxylatether enthaltende Dispersion
|
US20070224627A1
(en)
|
2006-03-23 |
2007-09-27 |
Lawrence Horowitz |
Facilitation of translocation of molecules through the gastrointestinal tract
|
CA2655372A1
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc. |
Il-17 and il-23 antagonists and methods of using the same
|
EA200870538A1
(ru)
|
2006-06-14 |
2009-04-28 |
Имклоун Системз Инкорпорейтед |
Лиофилизированные композиции анти-egfr антител
|
ES2531933T3
(es)
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
US8355333B2
(en)
|
2006-08-31 |
2013-01-15 |
Ciena Corporation |
Methods and systems for session initiation protocol control of network equipment
|
BRPI0719250A2
(pt)
|
2006-10-12 |
2015-06-16 |
Wyeth Corp |
Métodos e composições com opalescência reduzida.
|
EP2094729A1
(en)
|
2006-12-11 |
2009-09-02 |
F.Hoffmann-La Roche Ag |
Abeta antibody parenteral formulation
|
AU2008232902B2
(en)
|
2007-03-30 |
2013-10-03 |
Medlmmune, Llc |
Antibody formulation
|
GB0707938D0
(en)
|
2007-04-25 |
2007-05-30 |
Univ Strathclyde |
Precipitation stabilising compositions
|
EP3461500A1
(en)
|
2007-06-14 |
2019-04-03 |
Biogen MA Inc. |
Natalizumab antibody formulations
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
ES2755376T3
(es)
*
|
2007-11-21 |
2020-04-22 |
Univ Oregon Health & Science |
Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
|
JP5490714B2
(ja)
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
KR101615935B1
(ko)
|
2007-12-14 |
2016-04-28 |
노보 노르디스크 에이/에스 |
인간 nkg2d에 대한 항체 및 그것의 용도
|
BRPI0820819B1
(pt)
|
2007-12-21 |
2021-06-08 |
F. Hoffmann-La Roche Ag |
formulação de anticorpos humanizados b-ly 1 e seu uso
|
WO2009083225A2
(en)
|
2007-12-28 |
2009-07-09 |
Biolnvent International Ab |
Formulation
|
US8268972B2
(en)
|
2008-02-20 |
2012-09-18 |
G2 Inflammation Pty Ltd |
Humanized anti-C5aR antibodies
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
US8287861B2
(en)
|
2008-06-30 |
2012-10-16 |
Novo Nordisk A/S |
Anti-human interleukin-20 antibodies
|
UA112050C2
(uk)
|
2008-08-04 |
2016-07-25 |
БАЄР ХЕЛСКЕР ЛЛСі |
Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
|
SI2331090T1
(en)
|
2008-09-19 |
2018-04-30 |
Pfizer Inc. |
Stable liquid antibody formulation
|
RU2011126338A
(ru)
|
2008-11-28 |
2013-01-10 |
Эбботт Лэборетриз |
Стабильные композиции антител и способы их стабилизации
|
EP2196476A1
(en)
|
2008-12-10 |
2010-06-16 |
Novartis Ag |
Antibody formulation
|
AU2009327338B2
(en)
|
2008-12-19 |
2015-07-02 |
Takeda Pharmaceutical Company Limited |
TFPI inhibitors and methods of use
|
US8618263B2
(en)
|
2008-12-22 |
2013-12-31 |
Novo Nordisk A/S |
Antibodies against tissue factor pathway inhibitor (TFPI)
|
CA2745317C
(en)
|
2008-12-22 |
2019-03-05 |
Ida Hilden |
Antibodies against tissue factor pathway inhibitor
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
EP2442798A4
(en)
|
2009-06-18 |
2013-03-13 |
Wyeth Llc |
LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS
|
DK2473527T3
(en)
|
2009-09-03 |
2017-03-06 |
Ablynx Nv |
STABLE FORMULATIONS OF POLYPEPTIDES AND APPLICATIONS THEREOF
|
EP2332995A1
(en)
|
2009-12-10 |
2011-06-15 |
Bayer Schering Pharma Aktiengesellschaft |
Neutralizing prolactin receptor antibodies and their therapeutic use
|
KR20120130757A
(ko)
|
2010-02-26 |
2012-12-03 |
노보 노르디스크 에이/에스 |
안정한 항체 함유 조성물
|
CA2976671C
(en)
*
|
2010-03-01 |
2021-01-12 |
Bayer Healthcare Llc |
Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
|
NZ603028A
(en)
|
2010-03-19 |
2014-11-28 |
Baxter Healthcare Sa |
Tfpi inhibitors and methods of use
|
CA2800188A1
(en)
|
2010-05-28 |
2011-12-01 |
Novo Nordisk A/S |
Stable multi-dose compositions comprising an antibody and a preservative
|
EP2673364A1
(en)
|
2011-02-11 |
2013-12-18 |
Baxter International Inc |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
KR101995302B1
(ko)
|
2011-04-01 |
2019-07-02 |
바이엘 헬스케어 엘엘씨 |
조직 인자 경로 억제제 (tfpi)에 대한 모노클로날 항체
|
AU2013235567A1
(en)
|
2012-03-22 |
2014-10-09 |
Baxalta GmbH |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
HUE037907T2
(hu)
|
2013-03-15 |
2018-09-28 |
Bayer Healthcare Llc |
TFPI elleni, pH-tartományon belül különbözõ kötõdésû antitestváltozatok javított farmakokinetika érdekében
|
EP3262075B1
(en)
|
2015-02-25 |
2024-03-13 |
Mogam Institute For Biomedical Research |
Novel antibody binding to tfpi and composition comprising the same
|
IL302353A
(en)
|
2015-08-19 |
2023-06-01 |
Pfizer |
TFPI inhibitory antibodies and their uses
|